Objective: To elaborate figures that highlight the microscopic appearance of amastigote forms of the genus Leishmania and other structures subject to confusion during the routine of the direct examination of tegumentary leishmaniasis (TL). Study Design: We reviewed imprint and scraping slides previously prepared from patients with a definite diagnosis. Smear examinations were performed with an immersion objective (×1,000) selecting structures of interest for photodocumentation and elaboration of the illustrations. Results: We elaborated two 13 × 17 cm figures containing photomicrographs of amastigote forms with typical and atypical morphology of Leishmania parasites and other microorganisms, mainly fungi in the yeast-like phase and bacteria which could be confused with amastigote forms during the direct examination. Conclusions: The production of material like we show here is important and should be encouraged because of the need for constant training of professionals working in the area of TL diagnosis.

Keywords:
Direct examination, Tegumentary leishmaniasis, Optical microscopy
1.
World Health Organization: Control of Leishmaniasis. WHO Technical Report Series 949. Geneva, WHO, 2010.
2.
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S: Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-596.
3.
Rosenblatt JE: Laboratory diagnosis of infections due to blood and tissue parasites. Clin Infect Dis 2009;49:1103-1108.
4.
Durdu M, Baba M, Seçkin D: More experiences with the Tzanck smear test: cytologic findings in cutaneous granulomatous disorders. J Am Acad Dermatol 2009;61:441-450.
5.
de Mello CX, Schubach AO, Madeira MF: Can yeast-like form of Sporothrix schenckii confuse the direct parasitological diagnosis of American cutaneous leishmaniasis? Rev Soc Bras Med Trop 2011;44:127.
6.
Markle WH, Makhoul K: Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician 2004;69:1455-1460.
7.
Ministério da Saúde: Manual de vigilância e controle da leishmaniose tegumentar Americana. Brasília, Ministério da Saúde, 2010.
8.
de Lima MB, Schubach A, Francesconi-do-Valle AC, Gutierrez-Galhardo MC, Schubach TM, Conceição-Silva F, et al: Positive Montenegro skin test among patients with sporotrichosis in Rio de Janeiro. Acta Trop 2005;93:41-47.
9.
de Mello CX, Schubach AO, de Oliveira RV, Conceição-Silva F, Pimentel MI, Lyra MR, E Vasconcellos EC, de Fátima Madeira M: Comparison of the sensitivity of imprint and scraping techniques in the diagnosis of American tegumentary leishmaniasis in a referral centre in Rio de Janeiro, Brazil. Parasitol Res 2011;109:927-933.
10.
Vannier-Santos MA, Martiny A, de Souza W: Cell biology of Leishmania spp.: invading and evading. Curr Pharm Des 2002;8:297-318.
11.
Ziaie H, Sadeghian G: Isolation of bacteria causing secondary bacterial infection in the lesions of cutaneous leishmaniasis. Indian J Dermatol 2008;53:129-131.
12.
Cagnini DQ, Rodrigues MMP, Palumbo MIP, Heckler MCT, Peixoto AS, Amorim RL, Machado LHA: Diagnóstico citológico e tratamento da esporotricose felina: relato de caso. Vet e Zootec 2012;19:186-191.
13.
Daneshbod Y, Dehghani SJ, Daneshbod K: Bone marrow aspiration findings in kala-azar. Acta Cytol 2010;54:12-24.
14.
Kahama-Maro J, D'Acremont V, Mtasiwa D, Genton B, Lengeler C: Low quality of routine microscopy for malaria at different levels of the health system in Dar es Salaam. Malar J 2011;10:332.
15.
Nateghpour M, Edrissian G, Raeisi A, Motevalli-Haghi A, Farivar L, Mohseni G, Rahimi-Froushani A: The role of malaria microscopy training and refresher training courses in malaria control program in Iran during 2001-2011. Iranian J Parasitol 2012;7:104-109.
16.
World Health Organization: Malaria Microscopy Quality Assurance Manual - version 1. Geneva, WHO, 2008.
17.
Ministério da Saúde: Manual de diagnóstico laboratorial da malária. Brasília, Ministério da Saúde, 2009.
18.
Ministério da Saúde: Atlas de leishmaniose tegumentar Americana: diagnósticos clínico e diferencial. Brasília, Ministério da Saúde, 2006.
19.
World Health Organization: Informal consultation on quality control of malaria microscopy. Geneva, WHO, 2006.
20.
São Thiago PT, dos Santos JI, Steindel M: Histoplasmosis at the oral cavity simulating mucocutaneous leishmaniasis. Rev Soc Bras Med Trop 1998;31:225-229.
21.
Bonifaz A, Vázquez-González D, Perusquía-Ortiz AM: Endemic systemic mycoses: coccidioidomycosis, histoplasmosis, paracoccidioidomycosis and blastomycosis. J Dtsch Dermatol Ges 2011;9:705-714.
22.
Morris-Jones R: Sporotrichosis. Clin Exp Dermatol 2002;27:427-431.
23.
Pang KR, Wu JJ, Huang DB, Tyring SK: Subcutaneous fungal infections. Dermatol Ther 2004;17:523-531.
24.
Agudelo SP, Restrepo S, Velez ID: Cutaneous New World leishmaniasis-sporotrichosis coinfection: report of 3 cases. J Am Acad Dermatol 1999;40:1002-1004.
25.
Fontes CO, Carvalho MA, Nicoli JR, Hamdan JS, Mayrink W, Genaro O, Carmo LS, Farias LM: Identification and antimicrobial susceptibility of micro-organisms recovered from cutaneous lesions of human American tegumentary leishmaniasis in Minas Gerais, Brazil. J Med Microbiol 2005;54:1071-1076.
26.
Luz ZM, Carneiro M, Schall V, Rabello A: The organization of health services and visceral leishmaniasis: an integrated intervention to improve diagnosis and treatment. Cad Saude Publica 2009;25:1177-1184.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.